Pegasys Growth Strategy Will Focus On HIV/HCV Co-Infection And Hepatitis B

Roche's pegylated interferon product has captured 52% of total Rxs. APRICOT study in HIV/HCV co-infection shows Pegasys/Copegus (ribavirin) combo therapy yields 40% sustained virologic response.